BioStem director gets 7,671 shares from RSUs
Rhea-AI Filing Summary
BioStem Technologies, Inc. (BSEM) director Rayna Lesser Hannaway reported the vesting and exercise of 7,671 Restricted Stock Units into 7,671 shares of common stock on August 27, 2026. Each RSU represented a contingent right to one share and vested on that date, with no cash exercise price reported. Following the transaction, Hannaway directly holds 7,671 common shares and no remaining RSUs from this grant.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 7,671 shares
Net Buy
2 txns
Insider
LESSER HANNAWAY RAYNA
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F1, F2 | 7,671 | $0.00 | $0.00 |
| Exercise | Common Stock | 7,671 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 0 shares (Direct);
Common Stock — 7,671 shares (Direct)
Footnotes (2)
- F1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F2. These restricted stock units vested on August 27, 2026.
Key Figures
Restricted Stock Units exercised: 7,671 units
Common Stock acquired from RSUs: 7,671 shares
Exercise price per share: $0.00 per share
+1 more
4 metrics
Restricted Stock Units exercised
7,671 units
RSUs vested and converted on August 27, 2026
Common Stock acquired from RSUs
7,671 shares
Shares received upon RSU exercise on August 27, 2026
Exercise price per share
$0.00 per share
Reported for the RSU-to-common-stock conversion
Common shares owned after transaction
7,671 shares
Direct ownership following the August 27, 2026 transaction
Key Terms
Restricted Stock Units, derivative security, Form 4, Rule 10b5-1
4 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
Rule 10b5-1 regulatory
"aff_10b5_one is the filing's document-level Rule 10b5-1 checkbox"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
FAQ
What insider transaction did BSEM director Rayna Lesser Hannaway report on this Form 4?
Rayna Lesser Hannaway reported the vesting and exercise of 7,671 Restricted Stock Units into 7,671 shares of BioStem Technologies common stock on August 27, 2026, at a reported exercise price of $0.00 per share as part of equity compensation.
What happened to the 7,671 Restricted Stock Units reported for BSEM?
The 7,671 Restricted Stock Units vested and were exercised or converted into 7,671 shares of BioStem Technologies common stock on August 27, 2026. Each RSU represented a contingent right to receive one share of common stock.
Was the BSEM Form 4 transaction an open-market buy or sell?
The Form 4 reports an exercise/conversion of derivative securities (Restricted Stock Units) into common stock, not an open-market purchase or sale. The transaction code is M, and the exercise price is reported as $0.00 per share.
Did the BioStem Technologies (BSEM) Form 4 indicate use of a Rule 10b5-1 trading plan?
No. The Form 4 indicates the Rule 10b5-1 checkbox is not checked, and the footnotes do not state that the transactions were made pursuant to a Rule 10b5-1 or other pre-arranged trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
